# Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy

> **NCT01768195** · PHASE4 · UNKNOWN · sponsor: **Peking University** · enrollment: 80 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Entecavir prophylaxis

## Key facts

- **NCT ID:** NCT01768195
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01768195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01768195, "Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01768195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*